Other languages AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Market Closed - Nyse Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
0.378 ^USD	-1.51%		-3.08%	-14.07%

Jun. 05	Transcript : AIM ImmunoTech Inc. - Special Call
May. 16	Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	Apr. 29
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Feb. 08
AIM ImmunoTech Says First Subject Enrolled in Phase 1b/2 Study of Pancreatic Cancer Combination Therapy	Jan. 22
Kellner Group Issues a Statement to the Shareholders	Jan. 03
Sector Update: Health Care	Dec. 29
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	Dec. 29
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 29
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	Dec. 29
AIM ImmunoTech Provides Update Regarding Annual Meeting	Nov. 28
AIM ImmunoTech Gets US Patents for Ampligen Cancer, ME/CFS Treatment Methods	Nov. 27
AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue	Nov. 21
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Nov. 21
AIM ImmunoTech Mails Letter to its Shareholders	Nov. 20
AIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen	Nov. 14
AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer	Nov. 08
AIM ImmunoTech Says Phase 1 Study on Ampligen Confirms Positive Findings for Breast Cancer Treatment	23-09-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Other languages

Filters